American Academy of Neurology
- Business Wire
Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute to their ability to…
Read More » - Health
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
Darmstadt, Germany: Data presented at AAN shows investigational evobrutinib significantly reduced blood neurofilament light chain (NfL) levels, which may predict…
Read More »